Literature DB >> 3828952

Growth rate analysis of lung metastases from histologically benign giant cell tumor of bone.

E Katz, M Nyska, E Okon, G Zajicek, G Robin.   

Abstract

A growth rate analysis of lung metastases of benign giant cell tumor (GCT) of bone, histologically indistinguishable from the primary benign tumor, is presented. The doubling time (DT) was 186 days in the first 13 months of growth, and 465 days in the last 4 months. These DTs are much longer than DT of lung metastases of any other tumors, and have a good correlation with a long survival time. Backward extrapolation showed that the lung metastases began to develop years before the primary tumor was diagnosed and treated. If this can be confirmed in a larger number of patients, it could be concluded that there will be no indication for amputation as a treatment for benign GCT whether or not lung metastases are present. The growth rate analysis supports the concept that these metastases might represent a benign process, and as such are a unique histologic and clinical phenomenon.

Entities:  

Mesh:

Year:  1987        PMID: 3828952     DOI: 10.1002/1097-0142(19870515)59:10<1831::aid-cncr2820591025>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.

Authors:  Shinji Tsukamoto; Andreas F Mavrogenis; Giulio Leone; Alberto Righi; Manabu Akahane; Piergiuseppe Tanzi; Akira Kido; Kanya Honoki; Yasuhito Tanaka; Davide Maria Donati; Costantino Errani
Journal:  Int Orthop       Date:  2018-08-11       Impact factor: 3.075

2.  Regulation of MMP-9 (92 kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone.

Authors:  V H Rao; R K Singh; J A Bridge; J R Neff; G B Schaefer; D C Delimont; C M Dunn; W G Sanger; B A Buehler; R Sawaya; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

3.  [Volume changes to the neck lymph node metastases in head-neck tumors. The evaluation of radiotherapeutic treatment success].

Authors:  G Liszka; U Thalacker; A Somogyi; G Németh
Journal:  Strahlenther Onkol       Date:  1997-08       Impact factor: 3.621

4.  [Regression of Yoshida sarcoma during normoxia and hypoxia after fractionated irradiation].

Authors:  V Strnad; F Kamprad; J Jahns; M Meyer; R Böhme; P Madaj-Sterba; M Kirschner; R Sauer
Journal:  Strahlenther Onkol       Date:  1997-03       Impact factor: 3.621

5.  Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities?

Authors:  Seethalakshmi Viswanathan; N A Jambhekar
Journal:  Clin Orthop Relat Res       Date:  2009-07-14       Impact factor: 4.176

6.  Growth of metastases of the mouse adenocarcinoma EO 771: an allometric relationship between growth of the primary tumors and their metastases.

Authors:  I D Bassukas; B Maurer-Schultze
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

7.  Case report 869. Benign metastasizing giant cell tumor of bone.

Authors:  T Nojima; N Takeda; T Matsuno; K Inoue; K Nagashima
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

8.  Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.

Authors:  M H Zheng; Y Fan; A Panicker; A Smith; T Robertson; S Wysocki; P Robbins; J M Papadimitriou; D J Wood
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

9.  Investigation of FGFR2-IIIC signaling via FGF-2 ligand for advancing GCT stromal cell differentiation.

Authors:  Shalini Singh; Mohini Singh; Isabella W Y Mak; Robert Turcotte; Michelle Ghert
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

10.  Expressional Analysis of GFP-Tagged Cells in an In Vivo Mouse Model of Giant Cell Tumor of Bone.

Authors:  S Singh; M Singh; I Mak; M Ghert
Journal:  Open Orthop J       Date:  2013-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.